This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended): A compound of formula I

$$R^{1}$$
 $X-Y-T$
 $D-G$
 O

in which

R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, -OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together can also be a spirocyclically bonded 3- to 6-membered carbocyclic ring,

 R^3 is H or A,



is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

D is phenyl, pyridyl or thienyl, which in each case is monosubstituted or disubstituted by Hal,

G is $(CH_2)_n$ or $(CH_2)_nNH$ -,

X is CONH,

Y is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

T is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl

| | | oxygen, | | |
|---------|---------|--|--|--|
| | A | is unbranched or branched alkyl having 1-10 carbon atoms and in which 1- | | |
| | | atoms are each optionally replaced by F, | | |
| | Hal | is F, Cl, Br or I, and | | |
| | n | is 0, 1 or 2; | | |
| or a ph | narmace | utically usable salt, or stereoisomer thereof, including mixtures thereof in all | | |
| ratios. | | | | |
| | | | | |
| | 2. | (Cancelled): | | |
| | | | | |
| | 3. | (Cancelled): | | |
| | | | | |
| | 4. | (Cancelled): | | |
| | | | | |
| | 5. | (Cancelled): | | |
| | | | | |
| | 6. | (Cancelled): | | |
| | | | | |
| | 7. | (Cancelled): | | |
| | | | | |
| | 8. | (Cancelled): | | |
| | | | | |
| | 9. | (Cancelled): | | |
| | | | | |
| | 10. | (Cancelled): | | |
| | | | | |
| | 11. | (Cancelled): | | |
| | | | | |
| | 12. | (Cancelled): | | |

(Cancelled):

13.

| | 14. | (Cancelled): | | |
|--|---------|---|--|--|
| | 15. | (Cancelled): | | |
| | 16. | (Cancelled): | | |
| | 17. | (Cancelled): | | |
| | 18. | (Cancelled): | | |
| | 19. | (Cancelled): | | |
| 2 | 20. | (Cancelled): | | |
| 2 | 21. | (Cancelled): | | |
| 2 | 22. | (Cancelled): | | |
| 7 | 23. | (Currently Amended): A compound according to Claim 1, wherein said | | |
| compou | nd is s | elected from: | | |
| | 1-N-[(4 | 4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2- | | |
| dicarbox | xamide | 2, | | |
| $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-(3-oxomorpholin-4-yl)phenyl]\}-(R)-(3-oxomorpholin-4-yl)phenyl]\}-(R)-(3-oxomorpholin-4-yl)phenyl]$ | | | | |
| pyrrolid | ine-1,2 | 2-dicarboxamide, | | |
| | 1-N-[(4 | 4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)- | | |
| pyrrolid | ine-1,2 | 2-dicarboxamide, | | |
| | 1-N-[(4 | 4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)- | | |
| pyrrolid | ine-1,2 | 2-dicarboxamide, | | |
| | 1-N-[(4 | 4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}- | | |

 $(R)\hbox{-pyrrolidine-1,2-dicarboxamide,}\\$

- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-piperidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,
- N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-oxazolidine-3, 4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-chloro-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-thiazolidine-3,4-dicarboxamide,$
- $3-N-[(4-chlorophenyl)]-4-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-1,1-dioxo-1\lambda^6-thiazolidine-3,4-dicarboxamide,$
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,
- 3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(S)-1,1-dioxo- $1\lambda^6$ -thiazolidine-3,4-dicarboxamide,
 - N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-

carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxamide,

1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(5-chloropyridin-2-yl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-4, 4-dimethoxypyrrolidine-1, 2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,$

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,\\$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,
- (3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)-phenylcarbamoyl] pyrrolidin-3-yl isobutyrate,
- (3R, 5R) 1 (4-chlorophenylcarbamoyl) 5 [4 (3-oxomorpholin-4-yl)-phenylcarbamoyl] pyrrolidin-3-yl propionate,
- $(3R, 5R) \hbox{-} 1 \hbox{-} (4 \hbox{-} chlorophenyl carbamoyl) \hbox{-} 5 \hbox{-} [4 \hbox{-} (3 \hbox{-} oxomorpholin-4 \hbox{-} yl) \hbox{-} phenyl carbamoyl] pyrrolidin-3 \hbox{-} yl acetate,$
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $4-N-[(4-chlorophenyl)]-5-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-4, 5-dicarboxamide,$
- $\label{lem:continuous} 4-N-[(4-chlorophenyl)]-5-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-2, 2-dimethyl-4, 5-dicarboxamide,$
- $4-N-[(4-chlorophenyl)]-5-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-dioxolane-2, 2-dimethyl-4, 5-dicarboxamide,$

- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1-BOC-piperazine-1,2-dicarboxamide,$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperazine-1, 2-dicarboxamide,$
- $1-N-[4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-1, 3-oxazinane-3, 4-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- 6-N-[(4-chlorophenyl)]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-4-oxopyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chlorophenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,
- N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-4-hydroxypyrrolidine-2-carboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-pyrrolidine-1, 2-dicarboxamide,$
- $2-N-[(4-chlorophenyl)]-1-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(S)-pyrrolidine-1, 2-dicarboxamide,$
- $N-(4-chlorophenyl)-(R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] a cetyl \} pyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl] acetyl\} pyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(2R,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,$
- $N-(4-chlorophenyl)-(2R,4S)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,\\$
- $N-(4-chlorophenyl)-(2S,4R)-1-\{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl\}-4-methoxypyrrolidine-2-carboxamide,\\$
- $1-N-[(4-chlorophenyl)]-2-N-\{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-dicarboxamide,

- 9 -

- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,$
- 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,
- $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-bromophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,$
- $1-N-[(4-chlorophenyl)]-2-N-\{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,$

1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide;

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-3-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\} piperidine-1, 3-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-3-N-\{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]\} piperidine-1,3-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-methyl-4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$


 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$

 $1-N-[(4-chlorophenyl)]-2-N-\{[2-(3-oxomorpholin-4-yl)phenyl]\}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,$

and pharmaceutically usable salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 24. (Cancelled):
- 25. (Cancelled):
- 26. (Currently Amended): A process for the preparation of compounds according to claim 1, said process comprising
- a) for the preparation of compounds of the formula I in which $\,W$ is $\,N$ and $\,G\,$ is $\,NH,\,$

a compound of formula II



in which

R¹, R², E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula III


in which

D is as defined in Claim 1,

or

b) for the preparation of compounds of formula I in which W is N,

a compound of formula II



in which

R¹, R², E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of formula VI

D-G-CO-L VI

| in which | 1 | - 1 | ٠ | • | | | ٠ |
|----------|---|-----|----|---|-----|---|---|
| | h | C | 11 | h | 337 | n | 1 |


D and G are as defined in Claim 1, and L is Cl, Br, I or a free or reactively functionally modified OH group,

| | and/or | | |
|--|---|--|--|
| | a base or acid of the formula I is converted into one of its salts. | | |
| | | | |
| | 27. | (Cancelled): | |
| | | | |
| | 28. | (Cancelled): | |
| | | | |
| | 29. | (Previously Presented): A medicament composition comprising at least one | |
| compo | | cording to claim 1 and one or more excipients and/or adjuvants. | |
| compo | | crowing to craim 1 and one of more entriprents and of adjustants. | |
| | 30. | (Previously Presented): A medicament composition comprising at least one | |
| 2011110 | | | |
| compound according to claim 1 and at least one further medicament active ingredient. | | | |
| | 2.1 | | |
| | 31. | (Cancelled): | |
| | 22 | | |
| | 32. | (Previously Presented): A kit comprising separate packs of: | |
| | (a) | an effective amount of a compound according to claim 1, | |
| | and | | |
| | (b) | an effective amount of a further medicament active ingredient. | |
| | | | |
| | 33. | (Cancelled): | |
| | | | |
| | 34. | (Cancelled): | |
| | | | |
| | 35. | (Cancelled): | |
| | | | |
| | 36. | (Cancelled): | |
| | | | |


- 37. (Cancelled):
- 38. (Cancelled):
- 39. (Cancelled):
- 40. (Previously Presented): A medicament composition according to Claim 30, wherein said at least one compound is 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or a pharmaceutically usable salt or stereoisomer thereof, including mixtures thereof in all ratios, and said at least one further medicament active ingredient is aspirin.
- 41. (Previously Presented): A method according to Claim 33, wherein 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable salt or stereoisomer thereof, including mixtures thereof in all ratios, and aspirin are administered to said patient.
 - 42. (Previously Presented): A compound according to claim 1, wherein

- G is -NH-, and
- X is CONH.
- 43. (Previously Presented): A compound according to claim 1, wherein R¹ is H, =O, COOA, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino.
- 44. (Previously Presented): A compound according to claim 1, wherein R² is H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.


- 45. (Previously Presented): A compound according to claim 1, wherein R³ is H.
- 46. (Previously Presented): A compound according to claim 1, wherein




47. (Previously Presented): A compound according to claim 1, wherein



48. (Previously Presented): A compound according to claim 1, wherein



49. (Previously Presented): A compound according to claim 1, wherein




50. (Previously Presented): A compound according to claim 1, wherein

$$\left(\begin{array}{c}\mathsf{E}\\\mathsf{W}\end{array}\right)$$
 is 2,5-dihydro-1*H*-pyrrole-1,5-diyl.

51. (Previously Presented): A compound according to claim 1, wherein

52. (Previously Presented): A compound according to claim 1, wherein



- 53. (Previously Presented): A compound according to claim 1, wherein E is piperazine-1,4-diyl.
- 54. (Previously Presented): A compound according to claim 1, wherein E is tetrahydrofuran-3,4-diyl.
- 56. (Previously Presented): A compound according to claim 1, wherein D is phenyl which is monosubstituted or disubstituted by Hal.
- 57. (Previously Presented): A compound according to claim 1, wherein D is pyridyl which is monosubstituted or disubstituted by Hal.
- 58. (Previously Presented): A compound according to claim 1, wherein D is thienyl which is monosubstituted or disubstituted by Hal.
- 59. (Previously Presented): A compound according to claim 1, wherein G is $(CH_2)_n$.
- 60. (Previously Presented): A compound according to claim 1, wherein G is $(CH_2)_nNH$ -.

| | 61. | (Cancelled): | | |
|--------|------------------|--|--|--|
| | 62. | (Cancelled): | | |
| | 63. (Cancelled): | | | |
| | 64. | (Cancelled): | | |
| | 65. | (Cancelled): | | |
| | 66. | (Cancelled): | | |
| | 67. | (Cancelled): | | |
| | 68. | (Cancelled): | | |
| | 69. | (Cancelled): | | |
| | 70. | (Previously Presented): A compound according to claim 1, wherein | | |
| | R^1 is H | H , =O, COOA, OH, OA, NH_2 , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N_3 . | | |
| ethyny | ıl, vinyl | , allyloxy, methylcarbonyloxy, acetamino, or methylsulfonylamino; | | |
| | R^2 is H | H, =O, OH, methoxy, or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms; | | |
| | D is pl | henyl which is monosubstituted or disubstituted by Cl, pyridyl which is | | |
| monos | substitut | ted or disubstituted by Cl, or thienyl which is monosubstituted or disubstituted | | |
| by Cl; | | | | |